This article was originally published in The Gray Sheet
Nets $37.2 mil. from initial public offering of 5.0 mil. shares of common at $8 each. The firm expects to submit a 510(k) later this year for its Reliance female urinary incontinence device ("The Gray Sheet" Feb. 21, p. 14)
You may also be interested in...
FDA debars Matthew Hebert, USPlabs co-owner “with primarily responsibilities over product packaging design,” for five years from importing dietary ingredients or other articles of food.
Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.
The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.